Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors

Next Previous
Trial Profile

Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patritumab Deruxtecan (Primary)
  • Indications Advanced breast cancer; Brain metastases; Breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms TUXEDO-3

Most Recent Events

  • 30 May 2025 According to a MEDSIR media release, results were presented as an oral presentationat the American Society of Clinical Oncology (ASCO) 2025 annual meeting, with select results simultaneously published in Nature Medicine.
  • 22 May 2025 According to Daiichi Sankyo Company media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25)
  • 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top